Maintenance Therapy Post-Stem Cell Transplantation for Patients with T-Cell Lymphomas.

IF 2.7 3区医学 Q2 HEMATOLOGY

Current Hematologic Malignancy Reports Pub Date : 2024-12-01 Epub Date: 2024-10-19 DOI:10.1007/s11899-024-00743-w

Zachary Braunstein, Jonathan E Brammer

{"title":"Maintenance Therapy Post-Stem Cell Transplantation for Patients with T-Cell Lymphomas.","authors":"Zachary Braunstein, Jonathan E Brammer","doi":"10.1007/s11899-024-00743-w","DOIUrl":null,"url":null,"abstract":"Purpose of review: Given the poor outcomes for peripheral T-cell lymphomas (PTCL), stem cell transplant (SCT) remains an important therapeutic approach. Post-SCT relapse is common and maintenance therapy post-SCT is increasingly being utilized. Here we review the use of post-SCT maintenance therapy for PTCL patients.Recent findings: Maintenance therapy is increasingly utilized to decrease post-SCT relapse and improve outcomes in PTCL. Ongoing and completed post-SCT maintenance trials utilizing agents such as romidepsin, brentuximab vedotin, duvelisib, and pembrolizumab have shown efficacy in decreasing relapse. Further, additional agents with efficacy in PTCL have emerged that may inform future maintenance approaches. Maintenance therapy is a promising approach to maintain response after SCT in PTCL. While several trials are ongoing to evaluate maintenance therapy in PTCL, current data suggests this may be an effective method to decrease post-SCT relapse.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":" ","pages":"276-284"},"PeriodicalIF":2.7000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11568030/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Hematologic Malignancy Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s11899-024-00743-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/19 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Given the poor outcomes for peripheral T-cell lymphomas (PTCL), stem cell transplant (SCT) remains an important therapeutic approach. Post-SCT relapse is common and maintenance therapy post-SCT is increasingly being utilized. Here we review the use of post-SCT maintenance therapy for PTCL patients.

Recent findings: Maintenance therapy is increasingly utilized to decrease post-SCT relapse and improve outcomes in PTCL. Ongoing and completed post-SCT maintenance trials utilizing agents such as romidepsin, brentuximab vedotin, duvelisib, and pembrolizumab have shown efficacy in decreasing relapse. Further, additional agents with efficacy in PTCL have emerged that may inform future maintenance approaches. Maintenance therapy is a promising approach to maintain response after SCT in PTCL. While several trials are ongoing to evaluate maintenance therapy in PTCL, current data suggests this may be an effective method to decrease post-SCT relapse.

查看原文本刊更多论文

T 细胞淋巴瘤患者干细胞移植后的维持疗法。

综述目的：鉴于外周T细胞淋巴瘤（PTCL）疗效不佳，干细胞移植（SCT）仍是一种重要的治疗方法。干细胞移植后复发很常见，因此干细胞移植后维持疗法的使用越来越多。在此，我们回顾了PTCL患者使用SCT后维持疗法的情况：最近的研究结果：维持疗法正被越来越多地用于减少截断后复发和改善PTCL的预后。目前正在进行和已经完成的截断后维持治疗试验使用了romidepsin、brentuximab vedotin、duvelisib和pembrolizumab等药物，结果显示这些药物在减少复发方面具有疗效。此外，还出现了更多对 PTCL 有疗效的药物，可为未来的维持治疗方法提供参考。维持治疗是一种很有希望的方法，可维持 PTCL SCT 后的反应。目前正在进行多项试验以评估 PTCL 的维持疗法，现有数据表明这可能是减少 SCT 后复发的有效方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Hematologic Malignancy Reports ONCOLOGY-HEMATOLOGY

CiteScore

6.00

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： his journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of hematologic malignancy. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as leukemia, lymphoma, myeloma, and T-cell and other lymphoproliferative malignancies. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.